Follow Smart Investors

💥 Alpha Binwani Capital Newsletter
Smart investors are already reading it. Join them.

•🔵 Trusted by Bloomberg & Reuters — Research relied on by global financial leaders

•🟢 Real-Time Market Edge — Timely insights and expert trend analysis

•🟠 Exclusive Strategies — High-value ideas and deep dives, now free

•🟣 Zero Cost — Premium intelligence with no fees or hidden catch

•🟡 Stay Ahead — Institutional-level insights delivered to your inbox

Join the professionals shaping smarter market moves.

Subscribe free: bit.ly/FreeAlphaNewsletter

#Finance #Investing #MarketInsights #WealthBuilding #Alpha #SmartMoney #FinancialIntelligence

Mounjaro’s CV Nod: Lilly’s 8% MACE Edge Over Trulicity Rewrites GLP-1 Cardiovascular Standards

💉 Eli Lilly has won FDA approval for Mounjaro to reduce the risk of major adverse cardiovascular events (MACE)—including cardiovascular death, heart attack and stroke—in adults with Type 2 diabetes, a population in which roughly one in three also has undetected cardiovascular disease. The label is underpinned by the phase 3 SURPASS-CVOT trial, a four-year, 13,000-patient study across 30 countries that marked the first head-to-head cardiovascular outcomes comparison between two incretin drugs rather than a placebo-controlled design. In SURPASS-CVOT, Mounjaro demonstrated non-inferiority to Lilly’s earlier GLP-1 franchise leader Trulicity and delivered an 8% lower rate of MACE versus Trulicity, which itself gained a cardiovascular-risk-reduction indication in 2020 after its 2014 diabetes approval

Warsh Says Fed May Have ‘Work to Do’ as Inflation Progress Fails to Convince

‼️ BREAKING: Fed Chair Kevin Warsh said the central bank may still have more work to do on inflation, arguing that financial conditions do not appear restrictive and recent price data have not yet established a convincing improvement in the underlying trend. He said the Fed must see inflation moving clearly and quickly toward its target, but did not indicate whether he would support a rate increase at next month’s meeting or provide further policy guidance.